Oats Raised Butyrate and Other Fatty Acids in People at Cardiometabolic Risk. Rice Did Not.

Low-gluten diets have gone mainstream, but most of them quietly drop a nutrient that your gut bacteria depend on: fiber. A new six-week randomized clinical trial published in The Journal of Nutrition suggests that choosing oats over rice as the backbone of a low-gluten diet makes a measurable difference, specifically in the circulating short-chain fatty acids (SCFAs) that researchers believe play a central role in cardiometabolic health.

Oat-rich low-gluten diet raised plasma butyrate, acetate, and propionate

SCFAs, including butyrate, acetate, and propionate, are produced when gut bacteria ferment dietary fiber. They are not merely waste products. Research published in Frontiers in Pharmacology has linked these metabolites to maintained intestinal integrity, reduced inflammation, and improved glucolipid metabolism. The question Mannila E et al. set out to answer was whether the fiber source, specifically oats versus rice, matters for how much of these molecules end up in circulation.

The answer, at least for plasma concentrations, was yes. Participants assigned to an oat-rich low-gluten diet saw statistically significant increases in plasma butyric acid compared to the rice group (p time x group = 0.033). Acetic and propionic acid concentrations also increased moderately within the oat group. Because SCFAs sit at the intersection of diet and cardiometabolic risk, influencing lipid metabolism, intestinal hormones, and immunological balance, these shifts are biologically meaningful even when the downstream inflammatory markers did not move in this trial.

Why people with cardiometabolic risk have the most to gain

The 69 participants enrolled in this trial were specifically selected for elevated cardiometabolic risk: they were overweight or obese and had high cholesterol or elevated blood pressure. This is exactly the population where lifestyle interventions targeting dietary patterns are most actively studied, and where the fiber-microbiome-SCFA axis may offer a practical, low-cost lever.

Oats brought two distinct advantages to the intervention. First, the oat group was designed to consume roughly 100 grams of oats daily, aiming for 6 grams of beta-glucans, the soluble fiber fraction uniquely concentrated in oats. Second, oats contributed phytochemicals absent from white rice, which in this trial, as in most real-world settings, was consumed in its refined rather than whole-grain form. The rice group therefore entered the trial at a structural disadvantage in terms of fiber delivery, and the SCFA data reflected that gap.

How a 6-week parallel-arm trial isolated these signals

The design was a single-blinded, randomized parallel-arm trial. Participants were assigned either an oat-rich or rice-rich low-gluten diet for six weeks, with both diets covering approximately 500 kilocalories of daily energy from the study grains. Blood was drawn fasting at baseline and at week six. Plasma SCFAs were quantified using ultra-high-performance liquid chromatography mass spectrometry (UHPLC-MS), which allowed the team to measure nine distinct acids including butyric, isobutyric, valeric, isovaleric, acetic, propionic, succinic, lactic, and heptanoic acids.

Fecal microbial communities were characterized by shotgun metagenomics on a Novaseq X Plus platform, analyzed with MetaPhlAn4. Functional potential was assessed with HUMAnN3 using the MetaCyc database. Inflammatory markers were quantified through a 45-cytokine panel using the Olink Target system. Randomized controlled trials of this kind are considered the most reliable design for isolating dietary effects from confounders in observational data.

An unexpected wrinkle emerged from the gut microbiome results. The rice group, not the oat group, showed higher Shannon diversity in fecal microbiota after the intervention (p time x group = 0.025). The researchers attributed this not to rice being broadly beneficial for microbial diversity, but to the rice diet representing a more radical departure from participants' habitual eating. Both groups had been eating oats regularly at baseline, so the oat intervention produced smaller disruptions to the established microbial community. Within the rice group, species including Ruminococcus bicirculans, a known beta-glucan utilizer, Bifidobacterium longum, and Eubacterium rectale all decreased significantly, shifts the authors characterized as potentially unfavorable.

Why inflammatory markers stayed flat despite rising SCFAs

One of the more puzzling results was the absence of any significant change in inflammatory markers across either group. A 45-cytokine panel is a broad net, yet nothing moved. The authors offered two plausible explanations: the sample size may have been underpowered to detect subtle shifts in low-grade inflammation, and the high inter-individual variation in cytokine levels likely obscured signals that a larger cohort might surface. As current research on dietary fibers and SCFAs has repeatedly demonstrated, linking changes in circulating SCFAs to downstream inflammatory outcomes is technically difficult, partly because the relationship is likely indirect and delayed.

The disconnect between rising plasma SCFAs and flat cytokine levels also raises a genuine biological question: are these SCFA increases large enough, and sustained long enough, to translate into anti-inflammatory effects? Six weeks may simply be too short. The authors note that longer intervention periods are needed to determine whether the microbiome changes observed are transient or permanent, and whether inflammatory effects eventually follow.

Next steps for oat-based diets and SCFA research

The most actionable finding for researchers is the confirmation that the fiber source in a low-gluten diet is not interchangeable. Replacing wheat with oats preserves, and in this cohort modestly elevated, the circulating SCFA profile. Replacing wheat with refined white rice does not. For clinicians advising patients with cardiometabolic risk who are pursuing low-gluten eating for symptom relief or preference, this distinction matters.

Larger trials are the immediate next step. The authors call specifically for studies in populations that do not regularly consume oats at baseline, because baseline oat consumption in this Nordic cohort likely compressed the measurable effect. They also suggest future studies measure high-sensitivity CRP and lipopolysaccharide as earlier-stage indicators of low-grade inflammation. Looking further ahead, targeting SCFA pathways through nutritional therapy is attracting growing interest as a low-risk strategy for managing cardiometabolic conditions, and this trial adds a practical dietary context to that effort. For now, if you are going gluten-light, the data suggest going oat-heavy too.

Evidence rating

EMERGING — 84/100

Caveats:

• Small trial of 69 participants; results may not generalize beyond Nordic-diet populations or those with regular baseline oat consumption.
• Plasma SCFA increases were not accompanied by detectable shifts in fecal microbiome composition, leaving the mechanism linking oat fiber to circulating SCFAs unclear.
• Six weeks may be insufficient to detect meaningful changes in inflammatory markers or confirm whether microbiome shifts are durable.
• Funding source was not disclosed; independent replication has not yet occurred.

Randomized controlled trial (n=69, 6 weeks, two parallel arms). The oat intervention produced statistically significant increases in plasma butyrate versus the rice comparator, supported by named species-level metagenomics and quantitative SCFA profiling, but no corresponding shifts in fecal microbial community structure or inflammatory markers were observed. Results are not yet independently replicated and generalizability is limited to populations with habitual oat consumption and Nordic dietary patterns.

References

1. Enni Mannila, Carlos Gómez-Gallego, Geraldson Muluh, et al. (2026). Oat-rich low-gluten diet modulates plasma short-chain fatty acids without significant changes in fecal microbiome or inflammatory markers – a randomized clinical trial in people with cardiometabolic risk. The Journal of Nutrition. https://doi.org/10.1016/j.tjnut.2026.101690
2. Yingdong Lu, Yang Zhang, Xin Zhao, et al. (2022). Microbiota-derived short-chain fatty acids: Implications for cardiovascular and metabolic disease. Frontiers in Cardiovascular Medicine. https://doi.org/10.3389/fcvm.2022.900381
3. Eline Birkeland, Sedegheh Gharagozlian, Jørgen Valeur, Anne-Marie Aas (2023). Short-chain fatty acids as a link between diet and cardiometabolic risk: a narrative review. Lipids in Health and Disease. https://doi.org/10.1186/s12944-023-01803-5
4. Klodian Dhana, Neelum T. Aggarwal, Robin M. Voigt, et al. (2025). Effect of weight loss through dietary interventions on cardiometabolic health in older adults. International Journal of Obesity. https://doi.org/10.1038/s41366-025-01902-6
5. Sustainable Diets and Cardiometabolic Health (PlanetDiet) – ClinicalTrials.gov. clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT05445217
6. Effects of Dietary Fibers on Short-Chain Fatty Acids and Gut Microbiota Composition in Healthy Adults: A Systematic Review – PMC. mdpi.com. https://www.mdpi.com/2072-6643/12/5/1381/htm
7. Antonio Vacca, Gabriele Brosolo, Stefano Marcante, et al. (2026). Gut Microbiota and Short-Chain Fatty Acids in Cardiometabolic HFpEF: Mechanistic Pathways and Nutritional Therapeutic Perspectives. Nutrients. https://doi.org/10.3390/nu18020321